2016-02-18 15:03:22 UTC

How to Talk with Your Patients About PPIs and Dementia

July 20, 2017

Updated information regarding concerns among patients about the use of PPIs.

*Updated July 2017 per new research.

A 2016 study published in JAMA Neurology, “Association of Proton Pump Inhibitors With Risk of Dementia,” has raised questions among patients and health-care professionals.

A 2017 study published in Gastroenterology, "Association Between Proton Pump Inhibitor Use and Cognitive Function in Women," did not find convincing data the PPI use increases the risk of dementia. 

Here are some notes on interpreting the studies and what patients need to know.

The 2016 study, from Germany, is based upon insurance claims data and demonstrates a statistical association of dementia and long-term PPI use, not causation. Additional studies will need to be performed to prove that avoiding PPIs prevents dementia from developing.

This study, like most PPI-adverse effect studies, focuses on long-term users. Clinicians should recognize that PPIs are highly effective in treating acid-related disorders and also that there are few hard indications for long-term PPI use, including truly refractory GERD (with an abnormal pH study), Barrett’s esophagus, Zollinger-Ellison syndrome, idiopathic ulcers and, arguably, as prophylaxis against bleeding in select patients. 

The 2017 study looked at 13,864 participants from the Nurses’ Health Study II who completed testing on cognitive function, which is key predictor of the risk of dementia later in life. The study did not find convincing evidence that PPI use was associated with cognitive function and refutes the suggestion of the 2016 study that PPI use increases dementia risk. 

Patients taking PPIs for a diagnosed medical condition can be reassured by this new evidence as well as the continued research on long-term PPI use. The key points about safely using PPIs remain the same. 

Talking to Your Patients

  1. Reassure patients that you prescribed a PPI for a clear-cut indication, in the lowest possible dose, and for an appropriate period of time (lowest dose, shortest time). This advice echoes that offered by AGA and ABIM in the Choosing Wisely campaign. 
  2. Educate patients not to ask “what side effects do PPIs have?” but rather “is it really indicated?” Reassure patients that, when PPIs are indicated, benefits outweigh risks.
  3. Keep conversation channels open with patients. When patients require long-term use of PPIs, the medication should not be stopped without a discussion with you about the risks and benefits. 
  4. Recommend that patients also consider life-style modifications that may reduce or eliminate the need for PPIs for long-term use, as was concluded in the study “Lifestyle Intervention in Gastroesophageal Reflux Disease.”

More on Barrett's Esophagus

Porcine Esophageal Submucosal Gland Culture Model Shows Capacity for Proliferation and Differentiation

Oct. 22, 2017

We describe a novel porcine 3-dimensional culture model that reproduces esophageal submucosal gland proliferation in vivo associated with cancer and injury.

Cost Effectiveness of Screening Patients With Gastroesophageal Reflux Disease for Barrett’s Esophagus With a Minimally Invasive Cell Sampling Device

Sept. 1, 2017

We found Cytosponge screening with endoscopic confirmation to be a cost-effective strategy.

Late Recurrence of Barrett’s Esophagus After Complete Eradication of Intestinal Metaplasia is Rare: Final Report From Ablation in Intestinal Metaplasia Containing Dysplasia Trial

Sept. 1, 2017

Endoscopic surveillance of patients with BE treated with radiofrequency ablation will likely be of diminishing value as the time since ablation grows.